Press Releases Regulus Therapeutics Inc.

Equities

RGLS

US75915K3095

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
2.27 ^USD	+1.79%		-1.30%	+77.34%

May. 06	Regulus Therapeutics Advances to Cohort 4 of Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	CI
Mar. 21	Regulus Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	May. 06	PR
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series	Apr. 30	PR
Regulus: Q4 Earnings Snapshot	Mar. 21	AQ
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates	Mar. 21	PR
Emerging Companies: Key Developments and Investment Insights RGLS, INBS, VTAK, DYAI, TCBP	Mar. 14	AQ
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity	Mar. 12	PR
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Mar. 12	PR
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Jan. 02	PR
Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference	Nov. 22	PR
Regulus: Q3 Earnings Snapshot	Nov. 09	AQ
Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates	Nov. 09	PR
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	Nov. 03	AQ
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Nov. 02	PR
Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	23-10-19	PR
Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease	23-09-21	AQ
Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)	23-09-20	PR
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease	23-09-14	AQ
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)	23-09-13	PR
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences	23-09-05	PR
Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023	23-08-23	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Regulus Therapeutics Inc.

Equities

RGLS

US75915K3095

Press Releases

Filters